In the published article, there was an error in the Funding statement. The original funding statement is as follows: “The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Research Foundation of Korea (NRF) grant, funded by the Korean government (MSIT) (2017R1A2B4008178). Additionally, this research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HA15C0007).”
The correct Funding statement appears below.
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Research Foundation of Korea (NRF) grant, funded by the Korean government (MSIT) (2017R1A2B4008178, 2022R1F1A1075238). Additionally, this research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HA15C0007).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
neuroblastoma, PIRCHE, haploidentical hematopoietic stem cell transplantation, relapse/refractory, HLA mismatch
Citation
Seo ES, Jeong IH, Ju HY, Hyun JK, Lee JW, Yoo KH, Heo WY, Sung KW, Cho HW and Kang E-S (2025) Corrigendum: Predicted indirectly recognizable HLA epitopes scores and clinical outcomes after haploidentical stem cell transplantation in pediatric patients with relapsed neuroblastoma. Front. Immunol. 16:1565304. doi: 10.3389/fimmu.2025.1565304
Received
23 January 2025
Accepted
24 January 2025
Published
04 February 2025
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
16 - 2025
Updates
Copyright
© 2025 Seo, Jeong, Ju, Hyun, Lee, Yoo, Heo, Sung, Cho and Kang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hee Won Cho, hw87.cho@samsung.com; Eun-Suk Kang, eskang@skku.edu
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.